NeoGenomics (MEX:NEO) Issuance of Debt: MXN0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NEO NeoGenomics Inc MEX:NEO
69 GF Score
Price MXN176.40
GF Value MXN192.35
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Issuance of Debt?

NeoGenomics MEX:NEO 69 Issuance of Debt is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:NEO with a GF Score™ of 69/100 and a GF Value™ of MXN192.35 (Fairly Valued). The stock has 6 warning signs investors should review.

NeoGenomics's Issuance of Debt for the three months ended in Jun. 2026 was MXN0 Mil.

NeoGenomics's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was MXN0 Mil.

NeoGenomics Issuance of Debt Related Terms

NeoGenomics Issuance of Debt Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Issuance of Debt Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,860.09 0.00 0.00 0.00 0.00

NeoGenomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:NEO
69GF Score
NeoGenomics Inc MEX:NEO
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of MXN0 Mil mean?
NeoGenomics (MEX:NEO) has a Issuance of Debt of MXN0 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Issuance of Debt too high?
NeoGenomics' current Issuance of Debt is MXN0 Mil. Overall, NeoGenomics has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Issuance of Debt compare to WGS and CDNA?
NeoGenomics' Issuance of Debt of MXN0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Medical Diagnostics & Research company?
A good Issuance of Debt depends on the Medical Diagnostics & Research industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on NeoGenomics and its competitors. NeoGenomics's current Issuance of Debt is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (MEX:NEO) is currently considered Fairly Valued. The stock's GF Value™ is MXN192.35, compared to a current price of MXN176.40 — trading 8.3% below its estimated fair value. The current Issuance of Debt is MXN0 Mil. NeoGenomics' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Issuance of Debt is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (MEX:NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of MXN176.40 is trading 8.3% below its estimated GF Value™ of MXN192.35. GuruFocus considers NeoGenomics to be Fairly Valued.

Key valuation signals for MEX:NEO:

  • Issuance of Debt: MXN0 Mil
  • GF Value™: MXN192.35 vs. price of MXN176.40 (8.3% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:USANG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
69GF Score

Get the complete analysis for MEX:NEO

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN176.40
Price
MXN192.35
GF Value